571 related articles for article (PubMed ID: 17404086)
1. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
Wu CY; Wu MS; Chiang EP; Chen YJ; Chen CJ; Chi NH; Shih YT; Chen GH; Lin JT
Clin Cancer Res; 2007 Apr; 13(7):2054-60. PubMed ID: 17404086
[TBL] [Abstract][Full Text] [Related]
2. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
3. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
4. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
Wang CS; Wu TL; Tsao KC; Sun CF
Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
[TBL] [Abstract][Full Text] [Related]
5. Associations of matrix metalloproteinase-9 protein polymorphisms with lymph node metastasis but not invasion of gastric cancer.
Tang Y; Zhu J; Chen L; Chen L; Zhang S; Lin J
Clin Cancer Res; 2008 May; 14(9):2870-7. PubMed ID: 18451255
[TBL] [Abstract][Full Text] [Related]
6. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma.
Hayasaka A; Suzuki N; Fujimoto N; Iwama S; Fukuyama E; Kanda Y; Saisho H
Hepatology; 1996 Nov; 24(5):1058-62. PubMed ID: 8903375
[TBL] [Abstract][Full Text] [Related]
7. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer.
Tamura M; Oda M; Matsumoto I; Tsunezuka Y; Kawakami K; Ohta Y; Watanabe G
Ann Surg Oncol; 2004 Oct; 11(10):928-33. PubMed ID: 15383417
[TBL] [Abstract][Full Text] [Related]
8. Serum matrix metalloproteinase-9 level associated with stromal reaction in patients with gastric cancer.
Shen KH; Chi CW; Lo SS; Kao HL; Lui WY; Wu CW
Anticancer Res; 2000; 20(2B):1307-10. PubMed ID: 10810440
[TBL] [Abstract][Full Text] [Related]
9. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
10. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer.
Endo K; Maehara Y; Baba H; Yamamoto M; Tomisaki S; Watanabe A; Kakeji Y; Sugimachi K
Anticancer Res; 1997; 17(3C):2253-8. PubMed ID: 9216697
[TBL] [Abstract][Full Text] [Related]
11. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.
Waas ET; Wobbes T; Ruers T; Lomme RM; Hendriks T
Eur J Surg Oncol; 2006 Sep; 32(7):756-63. PubMed ID: 16650961
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of transforming growth factor beta1 are significantly correlated with venous invasion in patients with gastric cancer.
Lin Y; Kikuchi S; Obata Y; Yagyu K;
J Gastroenterol Hepatol; 2006 Feb; 21(2):432-7. PubMed ID: 16509870
[TBL] [Abstract][Full Text] [Related]
13. Activation of MMP-2 and MMP-9 in patients with oral squamous cell carcinoma.
Patel BP; Shah PM; Rawal UM; Desai AA; Shah SV; Rawal RM; Patel PS
J Surg Oncol; 2005 May; 90(2):81-8. PubMed ID: 15844188
[TBL] [Abstract][Full Text] [Related]
14. The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients.
Mroczko B; Kozłowski M; Groblewska M; Łukaszewicz M; Nikliński J; Jelski W; Laudański J; Chyczewski L; Szmitkowski M
Clin Chim Acta; 2008 Mar; 389(1-2):61-6. PubMed ID: 18155162
[TBL] [Abstract][Full Text] [Related]
15. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
Sliwowska I; Kopczyński Z
Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
[TBL] [Abstract][Full Text] [Related]
16. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer.
Hrabec E; Strek M; Nowak D; Hrabec Z
Respir Med; 2001 Jan; 95(1):1-4. PubMed ID: 11207010
[TBL] [Abstract][Full Text] [Related]
17. [Correlation of preoperative plasma levels of big endothelin-1 to prognosis of gastric carcinoma].
Teng XJ; Liu R; Zhang ZX; He JF; Shen ZX
Ai Zheng; 2008 Jan; 27(1):88-91. PubMed ID: 18184472
[TBL] [Abstract][Full Text] [Related]
18. Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer.
Aung PP; Oue N; Mitani Y; Nakayama H; Yoshida K; Noguchi T; Bosserhoff AK; Yasui W
Oncogene; 2006 Apr; 25(17):2546-57. PubMed ID: 16331256
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of changes in tumor markers, extracellular matrix, MMP-9 and VEGF in patients with gastric carcinoma.
Gao ZL; Zhang C; Du GY; Lu ZJ
Hepatogastroenterology; 2007; 54(77):1591-5. PubMed ID: 17708308
[TBL] [Abstract][Full Text] [Related]
20. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer.
Leppä S; Saarto T; Vehmanen L; Blomqvist C; Elomaa I
Breast Cancer Res Treat; 2005 Mar; 90(2):117-25. PubMed ID: 15803358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
